The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Jun 2014
Randomized Controlled TrialEffect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Bone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets bone metastases with high-energy, short-range α-particles. We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases. ⋯ Algeta and Bayer HealthCare Pharmaceuticals.